For the Inventor, By the Inventor

Enter assignee name

Westlake Village, CA, United States of America

Arcutis Biotherapeutics, Inc.

USPTO Granted Patents = 28

EPO Patents = 4

Trademarks = 5

Forward Citations = 93

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

David W Osborne (27 out of 43 patents)

Babak N Tofig (4 out of 4 patents)

Patrick Eugene Burnett (2 out of 2 patents)

4. David Reuben Berk (2 out of 2 patents)

5. Archie W Thurston, Jr (1 out of 1 patent)

6. Bhaskar Chaudhuri (1 out of 9 patents)

7. Saori Kato (1 out of 1 patent)

8. Saori Kato (1 out of 1 patent)

9. Jason Michael Carbol (1 out of 1 patent)

10. Herbert R Brinkman (1 out of 2 patents)

11. Frank Watanabe (1 out of 1 patent)

12. Howard Welgus (1 out of 1 patent)

Core Competencies:

Phosphodiesterase-4 Inhibitors

Roflumilast

Deep Dermal Drug Delivery

Aerosol Foams

Antifungal Properties

Pharmaceutical Compositions

Skin Penetration

Crystal Growth Inhibition

Topical Formulations

Improved Pharmacokinetic Profile

Laureth-4

Stable Formulations

28 patents: Sort by Forward Citations

1. 12697329 - Method for reducing side effects from administration of phosphodiesterase-4 inhibitors (2026-08-04),

2. 12685727 - Method for reducing side effects from administration of phosphodiesterase-4 inhibitors (2026-07-21),

3. 12458652 - Pharmaceutical compositions of spironolactone for deep dermal drug delivery (2025-11-04),

4. 12453721 - Topical roflumilast aerosol foams (2025-10-28),

5. 12390453 - Method for reducing side effects from administration of phosphodiesterase-4 inhibitors (2025-08-19),

6. 12336983 - Inhibition of crystal growth of roflumilast (2025-06-24),

7. 12329751 - Topical roflumilast formulation having antifungal properties (2025-06-17),

8. 12310956 - Topical roflumilast formulation having improved delivery and plasma half-life (2025-05-27),

9. 12257242 - Inhibition of crystal growth of roflumilast (2025-03-25),

10. 12220409 - Roflumilast formulations with an improved pharmacokinetic profile (2025-02-11),

11. 12161643 - Stable formulations of SHR0302 (2024-12-10),

12. 12144802 - Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug (2024-11-19),

13. 12083122 - Laureth-4 containing topical formulations (2024-09-10),

14. 12053481 - Compositions and methods for deep dermal drug delivery (2024-08-06),

15. 12042558 - Method and formulation for improving roflumilast skin penetration lag time (2024-07-23),

Company Overview

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company based in Westlake Village, California, focused on developing innovative therapies for dermatological conditions. The company specializes in creating treatments that address unmet medical needs in skin diseases, leveraging advanced formulations and drug delivery systems. Arcutis is committed to improving the quality of life for patients through its research in dermatology, aiming to provide effective solutions for various skin disorders.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

28 Patents

#5 in Westlake Village, CA

#2,849 in California

#12,016 in US

#23,299 in the World

Westlake Village, CA, United States of America

Arcutis Biotherapeutics, Inc.

Forward Citations = 93

12 inventors:

David W Osborne (27 out of 43 patents)

Babak N Tofig (4 out of 4 patents)

Patrick Eugene Burnett (2 out of 2 patents)

4. David Reuben Berk (2 out of 2 patents)

5. Archie W Thurston, Jr (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Arcutis Biotherapeutics, Inc.. Retrieved from https://idiyas.com/company/arcutis-biotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…